Root canal therapy for the prevention of osteonecrosis of the jaws: An evidence-based clinical update

被引:9
作者
Kyrgidis, Athanassios [1 ]
Arora, Amit [2 ]
Lyroudia, Kleoniki [3 ]
Antoniades, Konstantinos [1 ]
机构
[1] Aristotle Univ Thessaloniki, Dept Oral & Maxillofacial Surg, Fac Dent, GR-54006 Thessaloniki, Greece
[2] Univ Sydney, Fac Dent, Dept Populat Oral Hlth, Sydney, NSW 2006, Australia
[3] Aristotle Univ Thessaloniki, Fac Dent, Dept Endodontol, GR-54006 Thessaloniki, Greece
关键词
endodontics; osteonecrosis of the jaw; prevention; root canal therapy; treatment; BISPHOSPHONATE-RELATED OSTEONECROSIS; SURGEONS POSITION PAPER; RISK-FACTORS; AMERICAN ASSOCIATION; BONE METASTASES; ZOLEDRONIC ACID; CANCER-PATIENTS; BREAST; HYPOTHESES; MANAGEMENT;
D O I
10.1111/j.1747-4477.2010.00280.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Osteonecrosis of the jaws is an adverse effect of bone preservation treatment. There is a sufficient body of evidence to associate osteonecrosis of the jaws development with dental extractions and trauma caused from ill-fitting dentures. In this review, we critically appraise available evidence about the clinical efficacy of root canal therapy in patients receiving bisphosphonates. We review a series of theories to explain why endodontic treatment is a safe clinical intervention to prevent osteonecrosis of the jaws in patients receiving bisphosphonates. Root canal therapy could postpone or even eradicate the need for dental extractions of carious teeth in patients on bisphosphonates who may develop osteonecrosis of the jaws. Patients receiving bisphosphonates should be offered the full range of preventive care to reduce their risk to both dental caries and periodontal disease, so that the need for both endodontic therapy and dental extractions will be reduced. Implementing such a strategy would require both practitioner and patient education through the combined efforts of medical and dental societies. Such an approach is justified, as the risk of compromising the oral health of patients on bisphosphonates undertaking endodontic treatment is negligible compared with the benefit from avoiding dental extractions.
引用
收藏
页码:130 / 133
页数:4
相关论文
共 27 条
  • [1] The Pathogenesis of Bisphosphonate-Related Osteonecrosis of the Jaw: So Many Hypotheses, So Few Data
    Allen, Matthew R.
    Burr, David B.
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (05) : 61 - 70
  • [2] Efficacy and Safety of Denosumab in Postmenopausal Women with Osteopenia or Osteoporosis: A Systematic Review and a Meta-analysis
    Anastasilakis, A. D.
    Toulis, K. A.
    Goulis, D. G.
    Polyzos, S. A.
    Delaroudis, S.
    Giomisi, A.
    Terpos, E.
    [J]. HORMONE AND METABOLIC RESEARCH, 2009, 41 (10) : 721 - 729
  • [3] RANKL inhibition for the management of patients with benign metabolic bone disorders
    Anastasilakis, Athanasios D.
    Toulis, Konstantinos A.
    Polyzos, Stergios A.
    Terpos, Evangelos
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (08) : 1085 - 1102
  • [4] Recent advances in Oral Oncology 2008; squamous cell carcinoma aetiopathogenesis and experimental studies
    Bagan, Jose V.
    Scully, Crispian
    [J]. ORAL ONCOLOGY, 2009, 45 (07) : E45 - E48
  • [5] AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS POSITION PAPER: BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAWS-2009 UPDATE: THE NEED TO REFINE THE BRONJ DEFINITION
    Colella, Giuseppe
    Campisi, Giuseppina
    Fusco, Vittorio
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2009, 67 (12) : 2698 - 2699
  • [6] Font RG, 2008, MED ORAL PATOL ORAL, V13, pE318
  • [7] A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma
    Henry, D.
    von Moos, R.
    Vadhan-Raj, S.
    Hungria, V.
    Spencer, A.
    Hirsh, V.
    Wang, J.
    Jun, S.
    Yeh, H.
    Dansey, R.
    [J]. EJC SUPPLEMENTS, 2009, 7 (03): : 12 - 12
  • [8] Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/JBMR.080205, 10.1359/jbmr.080205]
  • [9] Kos M., 2009, Biosci. Hypotheses, V2, P34, DOI [10.1016/j.bihy.2008.08.004, DOI 10.1016/J.BIHY.2008.08.004]
  • [10] Denosumab-related osteonecrosis of the jaws
    Kyrgidis, A.
    Toulis, K. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2011, 22 (01) : 369 - 370